We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Kromek Group Plc | LSE:KMK | London | Ordinary Share | GB00BD7V5D43 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.25 | -3.33% | 7.25 | 7.00 | 7.50 | 7.55 | 7.25 | 7.55 | 681,334 | 13:44:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Miscellaneous Metal Ores,nec | 17.31M | -6.1M | -0.0102 | -7.11 | 43.52M |
Date | Subject | Author | Discuss |
---|---|---|---|
31/5/2022 21:27 | Yes things seem to be turning for the better for long suffering shareholders. GLA | strategicinvestor2 | |
31/5/2022 21:07 | Kromek was sat in the epicentre of a pandemic with a supposedly unique detector. To fail to deliver any profits whatsoever from such an achievement is remarkable. To think Kromek will achieve future success is a ridiculous folly. The board know it, and proved it, by not buying any at 8p. Where’s the independent proof these biological detectors work? No proof, no sales = it’s blindingly obvious they don’t work and were used to lure in money at the last desperate fundraising. | aqc888 | |
31/5/2022 07:53 | Onwards and upwardsIMO DYOR GLASP | slicethepie | |
31/5/2022 07:13 | Kromek is currently sat right place right time right products. This will translate in to a significantly higher share price imho | senttothegallows | |
31/5/2022 04:03 | Hopefully we will hear more with the results on where they are at on restructuring the company divisionally that would facilitate carve out and separate valuation or potential take over of different parts of the business. This seems a sensible move for shareholders. Any view or knowledge on this ? Maybe already relatively separate ? IMHO DYOR | strategicinvestor2 | |
27/5/2022 07:45 | Does everyone who ever makes a post have to be a ramper or short? QP has been pro and anti Kromek over time, as have I. What’s driven the anti Kromek sentiment is the incompetence and misguidance of the board. There’s a possibility that things might turn around, but if it does, that turnaround will have nothing to do with the guidance the board issue. So much sheer nonsense has come out of their mouths, I’d rather have a donkey in the CEOs chair. | aqc888 | |
26/5/2022 13:26 | Can you repeat that please. | b00mb0y | |
26/5/2022 12:51 | He who POSTS negatively most when price is rising is normally short ?ouchALL IMHO. DYORSP | slicethepie | |
26/5/2022 11:41 | Remind me please. What is their visibility on PROFITABILITY for the next years. Because although they have MANY TIMES in the past said they have GOOD VISIBILITY on revenues - this has NEVER ONCE translated into profitability. | quepassa | |
26/5/2022 11:26 | He who posts negatively most when price is rising is normally short ...ouchALL IMHO. DYORSP | slicethepie | |
26/5/2022 11:15 | Remind me please. What is their visibility on PROFITABILITY for the next years. Because although they have MANY TIMES in the past said they have GOOD VISIBILITY on revenues - this has NEVER ONCE translated into profitability. | quepassa | |
26/5/2022 09:38 | Was reassuring that they have visibility of nearly 100% of next years revenue taking into account the orders pipeline. Hopefully as we go through the year new orders not currently on the books can lead to upward revisions. Let’s pray for a turnaround here. GLA IMHO DYOR | strategicinvestor2 | |
26/5/2022 09:31 | The most important and basic thing that every investor knows who invests in highly speculative, small-cap or penny shares. The absolute and vital importance that management have skin in the game. If they don't, their interests ARE NOT aligned with shareholders. They get the risk-free fat salaries with no downside risk to their personal wealth whilst shareholders take all the downside risk. It's the first rule which Nassim Taleb (renowned author of The Black Swan) expounds in his book, Skin in The Game. The essential need for sharing of both downside and upside risk between shareholders and management. ALL IMO. DYOR. QP | quepassa | |
26/5/2022 08:44 | So robust that he didn’t take the opportunity to top up at 8p! Don’t think there’s been an investor update in the last 5yrs of failure where there wasn’t imminent good news! | aqc888 | |
26/5/2022 08:44 | So why isn't the CEO buying then?? No real skin in the game. It's always re-assuring to see a CEO eat their own cooking. Not so reassuring when they don't. More shareholder dilution is in my opinion likely coming given massive £10m cash burn over 12 months. ALL IMO. DYOR. QP | quepassa | |
25/5/2022 10:55 | Onwards and upwards!ALL IMO. DYOR.SP | slicethepie | |
25/5/2022 10:28 | Cumulative..... So are the seven years of repeat losses. Or is it eight years now? I lost count. | quepassa | |
25/5/2022 10:09 | Excellent news on order and vote of confidence. A small order but these things are cumulative. Also be interesting on DARPA progress with the results on the pathogen development now over 12 months into the 28 month development… | strategicinvestor2 | |
25/5/2022 09:53 | $695k. Peanuts. RNS for such a tiny amount smacks of desperation. A far far cry from the 4/4/14 up to $159m contract. ALL IMO. DYOR. QP | quepassa | |
25/5/2022 09:38 | good news but this is not the big bazooka about the covid pathogens detection that we ve been waiting for- just to confirm | ali47fish | |
25/5/2022 08:48 | Well put , and long journeys are best accomplished by lots of steps in the correct direction. This backs up their recent optimistic outlook for current year, as covered in the ED analysis 10 days ago: | edmonda | |
25/5/2022 08:32 | Few bits of info on their website/blog | kwizza | |
25/5/2022 07:48 | My screen showing news but can't see any rns or even rns reach..nothing on company website. Only other thing is it can be research sometimes. | kooba |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions